Sign inJoin waitlistJoin the waitlist

KS

Kamya Sankar

Physician · Cedars-Sinai Medical Center

Credentials: · · · · · ·

History

Cedars-Sinai Medical Center
2022–Present

Hematology and Medical Oncology
University of Michigan
2019–2022
Internal Medicine
McGaw Medical Center of Northwestern University
2016–2019
Wayne State University School of Medicine
2012–2016

Research

Recent advances in the management of hepatocellular carcinoma
Review · Clinical and Molecular Hepatology · 2024 · First of 9 authors · Corresponding · 140 citations
Intersection of immune and oncometabolic pathways drives cancer hyperprogression during immunotherapy
Cancer Cell · 2023 · 135 citations
The role of biomarkers in personalized immunotherapy
Review · Biomarker Research · 2022 · Co-first of 6 authors · 83 citations

Nithya Ramnath
12 papers
Karen Reckamp
11 papers
MG
Michael Green
11 papers
AB
Alex Bryant
10 papers · 9 as a resident
GS
Garth Strohbehn
9 papers
DE
David Elliott
6 papers
Jun Gong
6 papers
Andrew Hendifar
5 papers
Arsen Osipov
5 papers
Kambiz Kosari
5 papers
Nicholas Nissen
5 papers
AQ
Angel Qin
4 papers

Clinical trials

Study of Bevacizumab in Combination With Chemoimmunotherapy and Atezolizumab in Patients With Extensive Stage Small Cell Lung Cancer and Liver Metastases
Principal investigator · Recruiting · Phase 2
Kamya Sankar
2024–2027
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2027–2032
Gilteritinib for the Treatment of ALK NSCLC
Site PI · Recruiting · Phase 1
University of Michigan Rogel Cancer Center
2024–2027
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Site PI · Recruiting · Phase 3
Eli Lilly and Company
2023–2031